XKDCT 086
Alternative Names: iPD-1-Claudin18.2-CAR-T; XKDCT-086Latest Information Update: 26 Jul 2023
At a glance
- Originator Synkangda Life
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Clinical Phase Unknown Solid tumours
Most Recent Events
- 01 Mar 2023 Clinical trials in Solid tumours (Late-stage disease, In adults, In the elderly, Second-line therapy or greater) in China (IV) (NCT05952375)
- 13 Jan 2023 Preclinical trials in Solid tumours in China (IV)
- 13 Jan 2023 Pharmacodynamics data from a preclinical study in Solid tumors released by Synkangda Life